Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-547,632 with Chemotherapy in Advanced NSCLC
NCT00074854Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CP-547632 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Efficacy (Likelihood of Positive Outcome). Started May 2002; status: completed.
02
Drugs
CP-547632
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00074854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074854.